Download PDF
Thromb Haemost 1987; 57(01): 123
DOI: 10.1055/s-0038-1651076
Letters to the Editor
Schattauer GmbH Stuttgart

The Incidence of Thrombotic Manifestations in AT III Abnormalities

Antonio Girolami
University of Padua, Medical School and Second Chair of Medicine, Padua, Italy
› Author Affiliations
Further Information

Publication History

Received 10 July 1986

Accepted after revision 01 October 1986

Publication Date:
06 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints
 

  • References

  • 1 Bauer KA, Ashenfurst JB, Chediak J, Rosemberg RD. Antithrombin “Chicago”: a functionally abnormal molecule with increased heparin affinity causing familial thrombophilia. Blood 1983; 62: 1242-1250
    PubMedGoogle Scholar
  • 2 Chasse JF, Esnard F, Guitton JD, Monray H, Perigois F, Fauconneau G, Gauthier F. An abnormal plasma antithrombin with no apparent affinity for heparin. Thromb Res 1984; 34: 297-302
    CrossrefPubMedGoogle Scholar
  • 3 Fischer AM, Gazengel C, Dautzenberg MD, Benhammo J, Beguin S, Vergoz D. A new case of abnormal antithrombin III (AT III): biological characteristics and thromboembolic accidents management. Thromb Haemostas 1983; 50: 358 (Abstr)
    PubMedGoogle Scholar
  • 4 Fischer AM, Cornu P, Sternberg C, Meriane F, Chafa O, Dautzenberg MD, Beguin S, Desnos M. Antithrombin III Alger: a new homozygous AT III variant. Thromb Haemostas 1986; 55: 218-221
    PubMedGoogle Scholar
  • 5 Girolami A, Pengo V, Patrassi GM, Cappellato G, Vianello C, Cartei L. Antithrombin III Padua: a “new” congenital antithrombin III abnormality with normal or near normal activity, normal antigen, abnormal migration and no thrombotic disease. Folia Haematol 1983; 110: 98-111
    PubMedGoogle Scholar
  • 6 Girolami A, Cappellato G, Vicarioto MA, Vergolani A, Traverso R. Behavior of antithrombin III abnormalities in the crossed immunoelectrophoretic system. Folia Haematol 1985; 112: 159-164
    PubMedGoogle Scholar
  • 7 Girolami A, Fabris F, Cappellato G, Sainati L, Boeri G. Antithrombin III Padua2: a new congenital abnormality with defective heparin co-factor activities but no thrombotic disease. Blut 1983; 47: 93-103
    CrossrefPubMedGoogle Scholar
  • 8 Girolami A, Marafioti F, Rubestello M, Vicarioto MA, Cappellato G, Maruccolo M. Antithrombin III Trento: a new congenital AT III abnormality with a peculiar crossed immunoelectrophoretic pattern in the absence of heparin. Acta Haematol 1984; 72: 73-82
    CrossrefPubMedGoogle Scholar
  • 9 Girolami A, Cappellato G, Vicarioto MA, Casonato S, Marafioti F. Associated von Willebrand’s disease as a possible cause of lack of thrombosis in AT III (AT III Trento). Blut 1986; 52: 29-33
    CrossrefPubMedGoogle Scholar
  • 10 Howarth DJ, Samson D, Stirling Y, Seghatchian MJ. Antithrombin III “Northwick Park”: a variant antithrombin with normal affinity for heparin but reduced heparin co-factor activity. Thromb Haemostas 1985; 53: 314-319
    PubMedGoogle Scholar
  • 11 Koide T, Takahashi K, Odami S, Ono T, Sakuragawa N. Isolation and characterization of a hereditary abnormal antithrombin III “antithrombin III Toyama”. Thromb Res 1983; 31: 319-328
    CrossrefPubMedGoogle Scholar
  • 12 Nagy I, Losonczy H. Three types of hereditary AT III deficiency. Thromb Haemostas 1979; 42: 187 (Abstr)
    PubMedGoogle Scholar
  • 13 Penner JA, Hassouna H, Hunter MJ, Chockley M. A clinically silent antithrombin III defect in an Ann Arbor family. Thromb Haemostas 1979; 42: 186 (Abstr)
    PubMedGoogle Scholar
  • 14 Tran TH, Bounameaux H, Bondeli C, Honkanen H, Marbet GA, Duckert F. Purification and partial characterization of a hereditary abnormal antithrombin III fraction of a patient with recurrent thrombophlebitis. Thromb Haemostas 1980; 44: 87-91
    PubMedGoogle Scholar
  • 15 Wolf M, Boyer C, Lavergne JM, Larrieu MJ. A new familial variant of Antithrombin III: Antithrombin III Paris. Br J Haematol 1982; 51: 285-295
    CrossrefPubMedGoogle Scholar